http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-036205-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5ddadb999be4f451dfc44d8e359d8f6a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-405 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 |
| filingDate | 2002-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2004-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-036205-A1 |
| titleOfInvention | CRYSTALLINE FORMS OF FLUVASTATIN SODIUM, PROCESS FOR PREPARATION, AND PHARMACEUTICAL COMPOSITION |
| abstract | Crystalline forms of sodium fluvastatin hydrates, referred to as polymorphic forms C, D, E and F. A crystalline polymorph of monosodium salt of acid (ñ) -7- (3- (4-fluorphenyl) -1- (1-methylethyl) -1H-indole-2-yl) -3,5-dihydroxy-6-heptenoic, which exhibits a characteristic X-ray powder diffraction pattern, with characteristic peaks expressed in d (L) values: 23.8 (vs) , 11.8 (w), 7.8 (vs), 7.6 (vw), 7.4 (vw), 6.4 (vw), 6.1 (vw), 5.90 (w), 5.00 (vw), 4.88 (w), 4.73 (m), 4.56 (w), 4.40 (vw), 4.12 (vw), 4.03 (vw), 3 , 96 (vw), 3.50 (vw), 3.36 (vw), 2.93 (vw), where (vs) = very strong intensity; (m) = medium intensity; (w) = weak intensity and (vw) = very weak intensity. A crystalline polymorph of monosodium salt of (ñ) -7- (3- (4-fluorphenyl) -1- (1-methylethyl) -1H-indole-2-yl) -3,5-dihydroxy-6-heptenoic acid, which exhibits a characteristic X-ray powder diffraction pattern, with characteristic peaks expressed in d (L) values: 24.6 (vs), 12.5 (w), 8.3 (vs), 7.4 (vw ), 6.2 (m), 4.97 (w), 4.85 (vw), 4.52 (vw), 4.40 (vw), 4.14 (vw), 3.96 (vw) , 3.41 (vw), 3.10 (vw), where (vs) = very strong intensity; (m) = medium intensity; (w) = weak intensity and (vw) = very weak intensity. A crystalline polymorph of monosodium salt of (ñ) -7- (3- (4-fluorophenyl) -1- (1-methylethyl) -1H-indole-2-yl) -3,5-dihydroxy-6-heptenoic acid, which may have a slight deviation with the characteristic peaks expressed in d (L) values in the X-ray powder diffraction pattern in the range of 24.6-26.2 (vs), 12.5-13.2 ( w), 8.3-8.9 (vs) and 6.2-6.7 (m), depending on the relative humidity that varies from 35 to 50%, where (vs) = very strong intensity; (m) = medium intensity; (w) = weak intensity. A crystalline polymorph of monosodium salt of (ñ) -7- (3- (4-fluorphenyl) -1- (1-methylethyl) -1H-indole-2-yl) -3,5-dihydroxy-6-heptenoic acid, which exhibits a characteristic X-ray powder diffraction pattern, with characteristic peaks expressed in d (L) values: 27.6 (m), 13.9 (vw), 9.2 (m), 8.5 (vw ), 8.1 (vw), 7.4 (vw), 6.9 (s), 6.1 (vw), 4.98 (m), 4.77 (m), 4.63 (m) , 4.15 (w), 4.03 (w), 3.97 (vw), 3.52 (vw), 3.33 (vw), 3.08 (vw), 2.99 (vw), where (s) = strong intensity; (m) = medium intensity; (w) = weak intensity and (vw) = very weak intensity. A crystalline polymorph of monosodium salt of (ñ) -7- (3- (4-fluorophenyl) -1- (1-methylethyl) -1H-indole-2-yl) -3,5-dihydroxy-6-heptenoic acid, which exhibits a characteristic X-ray powder diffraction pattern, with characteristic peaks expressed in d (L) values: 29.6 (w), 14.8 (vw), 9.9 (w), 8.6 (vw ), 8.3 (vw), 7.4 (s), 6.6 (vw), 6.2 (vw), 5.93 (w), 5.03 (m), 4.94 (m) , 4.35 (vw), 4.23 (w), 3.98 (vw), 3.54 (vw), 2.98 (vw), where (s) = strong intensity; (m) = medium intensity; (w) = weak intensity and (vw) = very weak intensity. A process for the preparation of highly crystalline Fluvastatin Form A sodium, which comprises treating an aqueous solution of monosodium salt of (ñ) -7- (3- (4-fluorophenyl) -1- (1-methylethyl) -1H-indole acid -2-yl) -3,5-dihydroxy-6-heptenoic, to effect at least minimal precipitation of the compound, followed by freeze-drying of the suspension or precipitated compound. Pharmaceutical compositions comprising these crystalline forms. |
| priorityDate | 2001-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 23.